Repatha Significantly Reduces CV Event Risk in High-Risk Patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy AMGN?
Source: PRnewswire
- Clinical Trial Results: In the VESALIUS-CV trial, Repatha significantly reduced the risk of cardiovascular events in high-risk patients, with a 31% reduction in the composite primary endpoint (CHD death, myocardial infarction, or ischemic stroke), highlighting its importance in high-risk primary prevention.
- LDL-C Reduction Effectiveness: The Repatha group achieved a median LDL-C level of 44 mg/dL at 96 weeks, compared to 105 mg/dL in the placebo group, demonstrating its significant advantage in cholesterol reduction and potentially offering new treatment options for early cardiovascular intervention.
- Secondary Endpoint Performance: Repatha showed a 31% reduction in heart attack risk, a 34% reduction in ischemia-driven revascularization, and a 33% reduction in ischemic stroke among secondary endpoints, further proving its potential in cardiovascular health management.
- Strategic Implications: Amgen emphasizes that earlier and more intensive LDL-C lowering is critical for preventing cardiovascular events, and the findings from Repatha support the new ACC/AHA guidelines, driving a strategic shift in cardiovascular disease management.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMGN
Wall Street analysts forecast AMGN stock price to rise
24 Analyst Rating
14 Buy
9 Hold
1 Sell
Moderate Buy
Current: 353.160
Low
280.00
Averages
363.10
High
425.00
Current: 353.160
Low
280.00
Averages
363.10
High
425.00
About AMGN
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Repatha Significantly Reduces CV Event Risk in High-Risk Patients
- Clinical Trial Results: In the VESALIUS-CV trial, Repatha significantly reduced the risk of cardiovascular events in high-risk patients, with a 31% reduction in the composite primary endpoint (CHD death, myocardial infarction, or ischemic stroke), highlighting its importance in high-risk primary prevention.
- LDL-C Reduction Effectiveness: The Repatha group achieved a median LDL-C level of 44 mg/dL at 96 weeks, compared to 105 mg/dL in the placebo group, demonstrating its significant advantage in cholesterol reduction and potentially offering new treatment options for early cardiovascular intervention.
- Secondary Endpoint Performance: Repatha showed a 31% reduction in heart attack risk, a 34% reduction in ischemia-driven revascularization, and a 33% reduction in ischemic stroke among secondary endpoints, further proving its potential in cardiovascular health management.
- Strategic Implications: Amgen emphasizes that earlier and more intensive LDL-C lowering is critical for preventing cardiovascular events, and the findings from Repatha support the new ACC/AHA guidelines, driving a strategic shift in cardiovascular disease management.
See More
Repatha Significantly Reduces Cardiovascular Event Risk in High-Risk Patients
- Cardiovascular Event Risk Reduction: In the VESALIUS-CV clinical trial, Repatha reduced the risk of first major adverse cardiovascular events by 31% in high-risk primary prevention patients, highlighting its critical role in cardiovascular disease prevention.
- Significant LDL-C Reduction: The Repatha treatment group achieved a median LDL-C level of 44 mg/dL at 96 weeks, compared to 105 mg/dL in the placebo group, indicating its substantial efficacy in cholesterol lowering, potentially offering better cardiovascular protection for patients.
- Strategic Importance of Early Intervention: The findings underscore the importance of early and more intensive LDL-C lowering strategies in high-risk patients without known atherosclerosis, which may effectively reduce risk before cardiovascular events occur.
- Broad Applicability: Since its approval in 2015, Repatha has been used in over 8 million patients globally, demonstrating its wide applicability and potential market opportunities in cardiovascular disease management.
See More
Repatha Significantly Reduces Cardiovascular Event Risk in High-Risk Patients
- Cardiovascular Event Risk Reduction: In a study involving 3,655 high-risk patients, Repatha significantly reduced the risk of first major adverse cardiovascular events by 31%, underscoring its critical role in high-risk primary prevention.
- Significant LDL-C Level Reduction: After 96 weeks of treatment, the median LDL-C level in the Repatha group was 44 mg/dL compared to 105 mg/dL in the placebo group, demonstrating Repatha's superior efficacy in cholesterol reduction, potentially offering better cardiovascular protection for patients.
- Strategic Importance of Early Intervention: The findings emphasize the importance of early and intensive LDL-C lowering strategies in high-risk patients without known atherosclerosis, which may effectively reduce the risk before cardiovascular disease onset.
- Broad Clinical Application: Since its approval in 2015, Repatha has been used in over 8 million patients globally, and the FDA expanded its indications in 2025, further solidifying its position in cardiovascular disease management.
See More
EMA's CHMP Suggests Expanding Therapeutic Use for Hympavzi
- EMA Recommendation: The European Medicines Agency (EMA) has recommended the extension of the therapeutic indication for the drug HYM-PAV-ZI.
- Therapeutic Use: This extension aims to broaden the potential applications of HYM-PAV-ZI in treating specific medical conditions.
See More
EMA's CHMP Reaffirms Decision to Deny Change in Marketing Authorization for Hetlioz (Tasimelteon)
EMA's Recommendation: The European Medicines Agency (EMA) has confirmed its recommendation to reuse a specific change in the marketing authorization process.
Marketing Authorization: This recommendation pertains to the marketing authorization for a product associated with the organization Hetlioz, which is linked to the treatment of certain conditions.
See More
Anthropic: A Standout Innovator in AI
- Significant User Growth: Anthropic's Claude language model boasts 19 million monthly active users on the desktop version compared to 7 million on mobile, indicating rapid adoption among enterprise clients and enhancing the company's market position.
- Revenue Surge: As of now, Anthropic's annual recurring revenue (ARR) has skyrocketed to $14 billion, a remarkable increase from $100 million in early 2024 and $1 billion in 2025, reflecting the success of its business model and strong market demand.
- Funding and Valuation: In February, Anthropic closed a $30 billion Series G funding round, valuing the company at $380 billion, surpassing several well-known firms like Coca-Cola and AMD, showcasing strong investor confidence in its future potential.
- Diverse Investment Channels: While Anthropic is a private company, making direct stock purchases challenging for ordinary investors, the KraneShares Artificial Intelligence and Technology ETF (AGIX) offers a way to gain indirect exposure to Anthropic, with AGIX outperforming the S&P 500.
See More
Repatha Significantly Reduces CV Event Risk in High-Risk Patients
- Clinical Trial Results: In the VESALIUS-CV trial, Repatha significantly reduced the risk of cardiovascular events in high-risk patients, with a 31% reduction in the composite primary endpoint (CHD death, myocardial infarction, or ischemic stroke), highlighting its importance in high-risk primary prevention.
- LDL-C Reduction Effectiveness: The Repatha group achieved a median LDL-C level of 44 mg/dL at 96 weeks, compared to 105 mg/dL in the placebo group, demonstrating its significant advantage in cholesterol reduction and potentially offering new treatment options for early cardiovascular intervention.
- Secondary Endpoint Performance: Repatha showed a 31% reduction in heart attack risk, a 34% reduction in ischemia-driven revascularization, and a 33% reduction in ischemic stroke among secondary endpoints, further proving its potential in cardiovascular health management.
- Strategic Implications: Amgen emphasizes that earlier and more intensive LDL-C lowering is critical for preventing cardiovascular events, and the findings from Repatha support the new ACC/AHA guidelines, driving a strategic shift in cardiovascular disease management.
See More
Repatha Significantly Reduces Cardiovascular Event Risk in High-Risk Patients
- Cardiovascular Event Risk Reduction: In the VESALIUS-CV clinical trial, Repatha reduced the risk of first major adverse cardiovascular events by 31% in high-risk primary prevention patients, highlighting its critical role in cardiovascular disease prevention.
- Significant LDL-C Reduction: The Repatha treatment group achieved a median LDL-C level of 44 mg/dL at 96 weeks, compared to 105 mg/dL in the placebo group, indicating its substantial efficacy in cholesterol lowering, potentially offering better cardiovascular protection for patients.
- Strategic Importance of Early Intervention: The findings underscore the importance of early and more intensive LDL-C lowering strategies in high-risk patients without known atherosclerosis, which may effectively reduce risk before cardiovascular events occur.
- Broad Applicability: Since its approval in 2015, Repatha has been used in over 8 million patients globally, demonstrating its wide applicability and potential market opportunities in cardiovascular disease management.
See More
Repatha Significantly Reduces Cardiovascular Event Risk in High-Risk Patients
- Cardiovascular Event Risk Reduction: In a study involving 3,655 high-risk patients, Repatha significantly reduced the risk of first major adverse cardiovascular events by 31%, underscoring its critical role in high-risk primary prevention.
- Significant LDL-C Level Reduction: After 96 weeks of treatment, the median LDL-C level in the Repatha group was 44 mg/dL compared to 105 mg/dL in the placebo group, demonstrating Repatha's superior efficacy in cholesterol reduction, potentially offering better cardiovascular protection for patients.
- Strategic Importance of Early Intervention: The findings emphasize the importance of early and intensive LDL-C lowering strategies in high-risk patients without known atherosclerosis, which may effectively reduce the risk before cardiovascular disease onset.
- Broad Clinical Application: Since its approval in 2015, Repatha has been used in over 8 million patients globally, and the FDA expanded its indications in 2025, further solidifying its position in cardiovascular disease management.
See More
EMA's CHMP Suggests Expanding Therapeutic Use for Hympavzi
- EMA Recommendation: The European Medicines Agency (EMA) has recommended the extension of the therapeutic indication for the drug HYM-PAV-ZI.
- Therapeutic Use: This extension aims to broaden the potential applications of HYM-PAV-ZI in treating specific medical conditions.
See More
EMA's CHMP Reaffirms Decision to Deny Change in Marketing Authorization for Hetlioz (Tasimelteon)
EMA's Recommendation: The European Medicines Agency (EMA) has confirmed its recommendation to reuse a specific change in the marketing authorization process.
Marketing Authorization: This recommendation pertains to the marketing authorization for a product associated with the organization Hetlioz, which is linked to the treatment of certain conditions.
See More
Anthropic: A Standout Innovator in AI
- Significant User Growth: Anthropic's Claude language model boasts 19 million monthly active users on the desktop version compared to 7 million on mobile, indicating rapid adoption among enterprise clients and enhancing the company's market position.
- Revenue Surge: As of now, Anthropic's annual recurring revenue (ARR) has skyrocketed to $14 billion, a remarkable increase from $100 million in early 2024 and $1 billion in 2025, reflecting the success of its business model and strong market demand.
- Funding and Valuation: In February, Anthropic closed a $30 billion Series G funding round, valuing the company at $380 billion, surpassing several well-known firms like Coca-Cola and AMD, showcasing strong investor confidence in its future potential.
- Diverse Investment Channels: While Anthropic is a private company, making direct stock purchases challenging for ordinary investors, the KraneShares Artificial Intelligence and Technology ETF (AGIX) offers a way to gain indirect exposure to Anthropic, with AGIX outperforming the S&P 500.
See More
